Very high levels of the suPAR protein in blood samples of coronavirus patients could be a new biomarker to predict those who will develop severe respiratory failure. Researchers say, the higher the suPAR level, the shorter the time before a patient needs intubation.
On Saturday, the FDA approved Houston Methodist to conduct transfused plasma therapy for the treatment of COVID-19. The plasma will be donated from recovered COVID-19 patients and transfused into those critically ill with the virus. Researchers have already begun recruiting donors in the Houston area who have recovered from coronavirus. The first donor was a patient in the Houston Metropolitan area who has been in good health for two weeks following COVID-19 infection.
A small group of people with Alzheimer's who received an experimental blood plasma infusion from young donors showed some improvements in their condition, researchers report.
A new measuring method has detected oxytocin at much higher rates in blood serum and plasma than researchers previously thought.
Researchers proposes a link between ionizing radiation and the development of Alzheimer's disease.
A new study find increased levels of Alzheimer's related Tau protein in children under the age of 18 who suffer early onset psychosis.